138 results about "Influenza virus A hemagglutinin" patented technology

The present invention relates to a combination of a priming composition and a boosting composition to prime and boost an immune response in a subject whereby the immune response resulting from administration of the priming composition to the subject is capable of being boosted. The priming composition comprises a DNA plasmid that comprises a nucleic acid molecule encoding an influenza virus hemagglutinin (HA) or an epitope-bearing domain thereof. The boosting composition comprises an influenza vaccine. The present invention also relates to a method to use such a combination to vaccinate a subject and to enhance an immune response to an influenza vaccine administered alone. Such a combination can elicit an immune response not only against at least one influenza virus strain from which the priming composition or boosting composition is derived but also to at least one heterologous influenza virus strain.

The present invention relates to an artificially synthesized gene optiHA containing codons for chicken partial tropism. Its reading frame contains 1707 bp nucleotides and encodes a total of 568 amino acids. The gene is compatible with H5 subtype highly pathogenic avian influenza virus A/ Goose/GuangDong/1/96(H5N1)[GD/1/96(H5N1)]hemagglutinin (HA) gene has a nucleotide homology rate of 70%, an amino acid homology rate of 100%, and encodes the H5 subtype Hemagglutinin (HA) protein of avian influenza virus GD/1/96 (H5N1). The invention also relates to the application of the gene as an immunogenic gene of H5 subtype influenza DNA vaccine and other genetic engineering vaccines.

The present invention relates to a fusion polypeptide comprising at least about 10 contiguous amino acid residues of an influenza virus hemagglutinin and at least about 5 contiguous amino acids of a naturally occurring GM-CSF molecule.

Provided herein are polypeptides comprising portions of the influenza virus hemagglutinin, compositions comprising such polypeptides that can be used as immunogens in vaccines and methods of their use to generate an immune response against multiple influenza subtypes in a subject.

The present invention provides a recombinant turkey herpesvirus modified by the presence of the cDNA encoding the hemagglutinin protein of avian influenza virus under a promoter. A poultry vaccine comprising the recombinant turkey herpesvirus described in the present invention can induce serological responses that may be easily detected by the hemagglutination inhibition assay but not by commercially available diagnostic ELISA kits; thus enabling easy differentiation between vaccination and field infection.

The invention provides a recombinant duck enteritis virus (DEV) vaccine strain CCTCC NO:V201125 named rDEVus78Ha-Re6 for expressing an avian influenza virus haemagglutinin (HA) gene, and a constructing method and application thereof. The vaccine strain is prepared by the following steps of: inserting a genetic fragment SV40-HA comprising the avian influenza virus HA gene and an SV40 promoter sequence into a spacer between a US7 gene and a US8 gene of a DEV by adopting a recombinant cloning technology; constructing a cosmid for inserting an SV40-HA expression frame between the US7 gene and theUS8 gene; and saving to obtain the recombinant DEV vaccine strain CCTCC NO:V201125 for expressing the avian influenza virus HA gene. The invention further relates to a method for constructing the recombinant DEV vaccine strain and application of the recombinant DEV vaccine strain to preparation of a vaccine for preventing duck viral enteritis and avian influenza.

The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza A virus group 1 subtypes selected from H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and H17 and variants thereof and one or more influenza A virus group 2 subtype selected from H3, H4, H7, H1, 0, H14 and H15 and variants thereof.

The invention provides a hemagglutinin (HA) protein neutralizing epitope mimic peptide of H5 subtype avian influenza viruses, a conserved derivative or active fragment or mutant sequence thereof, related coding sequence thereof and the use of the mimic peptide or the conserved derivative or active fragment or mutant sequence thereof in prevention and diagnosis.

Provided is a neutralising antibody which binds to and neutralises an H7 type influenza A virus. The nucleotide sequences of the light and heavy chain variable regions of the antibody are at least 75% identical to the nucleotide sequence of any one of SEQ ID NO: 38-55, 58 or 59, and the antibody can neutralise a human infection H7N9 influenza A virus haemagglutinin protein. Also provided is an efficient expression method for integrating an antibody into a cell such as a CHO cell, and a use for the antibody, a related haemagglutinin protein antigen binding fragment and an epitope in the diagnosis, treatment and prevention of human infection H7N9 influenza A virus infection.

Belonging to the technical field of biomedicine, the invention relates to a sequence and structure of a polypeptide able to specifically bind with influenza virus hemagglutinin protein, and application of the polypeptide in anti-influenza viruses. By expressing purified influenza virus hemagglutinin protein and screening a random peptide library with a phage display technology, a polypeptide specifically bound with influenza virus hemagglutinin and equipped with sequences numbered 1-18 can be obtained. As a hemagglutinin-binding peptide can hinder the combination of hemagglutinin and a host cell receptor, so the influenza virus can be inhibited from infecting the host cell. Thus, the invention also conducts an anti-influenza virus activity study to the hemagglutinin-binding peptide selected from the phase peptide library, and finds that a polypeptide H17, with a sequence of NH2-SHGRITFAYFAN-COOH, can effectively inhibit the influenza virus from infecting the host cell and is of small toxicity. Therefore, the hemagglutinin-binding peptide of the invention and the H17 polypeptide therein with an anti-influenza virus activity are expected to become novel treatment medicaments for treating diseases caused by influenza virus infection and reducing the hazards of diseases caused by influenza viruses.

The invention discloses a recombinant influenza virus and application thereof and provides a preparation method of the recombinant virus. The preparation method comprises the following steps: guiding an HA6 subtype influenza virus hemagglutinin encoding gene, an influenza virus neuraminidase (NA) gene and six genes including PB2, PB1, PA, NP, M and NS in an influenza virus into a host cell together, and packing to obtain the recombinant virus. The invention also discloses a detection method for detecting antibodies for inhibiting activities of seasonal influenza N1, N2, 2009H1N1N1 and 2013H7N9N9 enzymes by virtue of the recombinant virus. The detection method comprises the steps of sample treatment and result analysis. According to the invention, the immune response to NA of people can be rapidly and effectively measured, the operation is simple, the application is convenient, and viable technical support is provided for clinical detection and vaccine evaluation.

This invention discloses a latex agglutination kit to quickly detect H5 subtype of avian influenza virus. The anti monoclonal antibodies of H5 subtype of avian influenza virus hemagglutinin protein were coupled to the surface of carboxyl polystyrene latex particles using water-soluble carbodiimide, the methods about detection of H5 subtype of avian influenza virus were established, the latex agglutination detection kits of H5 subtype of avian influenza virus were prepared supplemented by other matching reagents. This kit was made up of box body and the body latex diagnostic reagents in the box, sample handling liquid A, sample handling liquid B, the positive control samples and negative control samples. This invention kit can directly detect the H5 subtype avian flu virus, with high specificity, high sensitivity, simple and rapid diagnosis, and other significant advantages.

The invention relates to polypeptide, protein or peptide-like medicine from influenza virus hemagglutinin, and a method of the polypeptide, belongs to the technical field of biological medicines, and in particular relates to eight influenza virus hemagglutinin fragment peptides which can block influenza virus infection and have the serial numbers SEQ ID NO.1 to SEQ ID NO.8. The fragment peptides can inhibit and block infection of different species and influenza viruses of different subtypes to a host, including multiple influenza virus strains such as highly pathogenic avian influenza virus, seasonal human influenza virus and the like. The invention provides the peptide sequence (including amino acid sequences of peptides and polynucleotide sequences of encoded peptides), derivative peptides (including amino acid sequences of peptides and polynucleotide sequences of encoded peptides), peptide compositions and independent or united applications of peptides in preventing or treating influenza virus, such as medicine combination of peptides provided by the invention and other anti-influenza medicines.

The invention belongs to the fields of detection technology of animal virology and epizootiology. The invention particularly relates to an H1-subtype influenza A virus double-antibody sandwich ELISA kit and an application. The kit of the invention comprises an enzyme label plate which contains anti-H1-subtype influenza A virus hemagglutinin, has a preservation number of CCTCC NO: C201106, and is coated by a monoclonal antibody, and a horseradish peroxidase labeled H1-subtype influenza A virus hemagglutinin monoclonal antibody is used as a second antibody. The invention discloses separation, amplification, inactivation, and purification methods of the H1-subtype influenza A virus, and preparation and purification methods of the H1-subtype influenza A virus hemagglutinin monoclonal antibody. The invention also discloses an H1-subtype influenza A virus double-antibody sandwich ELISA detection method.

The invention provides a loop-mediated isothermal amplification test method of an influenza A3 virus. The method comprises the following steps: a specificity primer sequence is designed according to an influenza A3 virus hemagglutinin gene, a sample RNA to be tested is extracted as the template to have LAMP reaction; the LAMP reaction result is analyzed; if the LAMP amplification result is positive, the sample to be tested contains the influenza A3 virus. The LAMP influenza A3 virus test method is characterized by convenience, economy, fastness, sensitivity and specificity with flexible and convenient result judgment, is applicable in clinical or laboratory diagnosis, and has broad application prospect.

The invention discloses an A-type H1 subtype influenza virus antibody blocking ELISA kit. The kit comprises: a) an A-type H1 subtype influenza virus A-Influ/JML-F9; b) a monoclonal antibody with strong specificity of an A-type H1 subtype influenza virus-resistant hemagglutinin protein; c) an antibody blocking ELISA core kit prepared from the monoclonal antibody of the A-type H1 subtype influenza virus-resistant hemagglutinin protein; and d) a sample diluting liquid, 10 times of a washing liquid, a substrate liquid A, a substrate liquid B, a reaction stop solution, a positive control sample and a negative control sample in the kit. The invention also discloses applications of the A-type H1 subtype influenza virus antibody blocking ELISA kit in A-type H1 subtype influenza virus antibody detection. The kit has strong specificity, high sensitivity, short detection time, easy and practical operation, and no need of being operated by a professional person. The kit is good in stability and long in retention period, and solves a problem of the A-type H1 subtype influenza virus antibody detection.

This invention relates to methods and products for the diagnosis, surveillance, prevention, and treatment of influenza A virus infections in animals and humans. More particularly, the invention relates to antibodies and related binding proteins for the detection, prevention and treatment of influenza A viruses. The monoclonal antibodies and related binding proteins of the invention are useful for the treatment of the highly pathogenic H5 subtypes of avian influenza virus (AIV).

The invention discloses a monoclonal antibody of anti-H9 subtype flu virus haemagglutinin protein, which is secreted by hybridoma cell strain 4D10 with the preserving number of CCTCC No: C2012152. The invention further discloses a double antibody sandwich ELISA test kit of H9 subtype flue virus and a detection method. The monoclonal antibody of anti-H9 subtype flu virus haemagglutinin protein is used as a primary antibody, a monoclonal antibody marked by horseradish peroxidase is used as a second antibody, and a separation, augmentation, inactivation and purification method of H9 subtype flue virus and a preparation and purification method of anti-H9 subtype flu virus haemagglutinin monoclonal antibody are disclosed. According to the test kit and the detection method disclosed by the invention, the H9 subtype flue virus can be detected directly, and the monoclonal antibody has the characteristics of being high in specificity, high in sensitivity, short in detection time, wide in detection sample range and the like.

The invention discloses an H1N1 swine influenza virus-resistant hemagglutinin protein monoclonal antibody, a hybridoma cell line and an antigen-capture enzyme linked immunosorbent assay (ELISA) kit. The monoclonal antibody is secreted by a hybridoma cell of which the collection number is CCTCC C2010121, and has high titer and specificity. The developed antigen-capture ELISA kit comprises a solid-phase vector coated with the monoclonal antibody, the H1N1 swine influenza virus-resistant hemagglutinin protein monoclonal antibody labeled by a horse radish peroxidase, substrate reaction solution of an enzyme, positive and negative controls, cleaning solution and reaction stop solution. The kit has high specificity and sensitivity, is easy to operate, can be used for the clinical and laboratory detection of large-scale H1N1 swine influenza viruses and has wide application prospect.